Novel Treatments for Chronic Viral Infections

ContraVir seeks to develop and commercialize novel drug treatments to improve the lives of patients suffering from chronic viral infections, with an initial focus on herpes zoster, or shingles, and hepatitis B.

Pipeline Newsroom Investors

 

Combination Therapies for Hepatitis B

ContraVir is developing potentially curative combination therapies for chronic hepatitis B based on novel antiviral compounds.

TXL™ CRV431 Opportunity

 

A Shingles Treatment with Best in Class Potential

Our lead candidate is Valnivudine™, a potent oral antiviral being developed for the treatment of herpes zoster, commonly known as shingles. Valnivudine™ is well-tolerated and has been shown to reduce PHN pain in Phase 2 trials.

About ContraVir

ContraVir is developing a portfolio of novel compounds against hepatitis B, including TXL™ (formerly CMX157), a highly potent analog of the successful antiviral drug tenofovir DF (Viread®), now in Phase 2 trials, and CRV431, a next generation cyclophilin inhibitor. ContraVir is also developing Valnivudine™ (formerly FV-100), now in Phase 3 trials, for the treatment of herpes zoster, or shingles, and the pain associated with shingles.